Abstract: The present disclosure generally relates to compositions, formulations, methods, and/or uses of nucleic acid vaccines, specifically nucleic acid vaccines (e.g., RNA, mRNA, DNA vaccines) encoding one or more proteins, peptides, fragments or variants thereof of SARS-CoV-2 for the prevention, alleviation and/or treatment and/or prevention of COVID-19, including mitigation of physiologic effects of infection and/or symptoms.

Abstract: A coronavirus vaccine based on controllable secretory expression of attenuated Salmonella, a preparation method therefor, and use thereof. The method includes constructing controllable and stable expression plasmids for secretory expression of different antigenic structural domain proteins of the new coronaviruses and their attenuated Salmonella expression strains, and then mixing various attenuated Salmonella antigen-presenting strains that can achieve controllable intracellular secretory expression in antigen-presenting cells. With the aid of a unique secretion system, a variety of different antigenic proteins can be secretory-expressed efficiently in antigen-presenting cells after oral gavaging. The secretory-expressed antigenic proteins can be efficiently processed and presented by the antigen-presenting cells, and finally activate/regulate the immune system to produce more potent antibodies to make the vaccine work.

Abstract: The present invention provides multimeric protein complex comprising three polypeptides each comprising N- to C-terminally: (i) a receptor-binding domain (RBD) of an S1 subunit of an S protein of a coronavirus, (ii) optionally a S2 subunit of an S protein of a coronavirus; and (iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a multimeric protein complex. The present invention further provides polynucleotides encoding the polypeptides of the multimeric protein complex, expression vectors, pharmaceutical compositions and uses of the multimeric protein complexes, such as a vaccine.

Abstract: Provided here are compositions for a bacterial artificial chromosome-based construct containing a replication-competent recombinant severe acute respiratory syndrome coronavirus-2 (rSARS-CoV-2) genome and methods of making such compositions and uses thereof. The rSARS-Cov-2 provided herein can be attenuated and safely worked with under BLS-2+ conditions.

Abstract: The present disclosure provides delivery vehicle compositions comprising hydroxyethyl-capped tertiary amino lipidated cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.

Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

Abstract: The present disclosure relates to HIV vaccines and methods of use thereof. Disclosed herein are methods of preventing an infection from a human immunodeficiency virus (HIV) using a commensal microbe antigen. Further disclosed herein is a method of boosting an immune response against a human immunodeficiency virus (HIV), the method comprising administering to a subject an effective amount of a first composition comprising a commensal microbe antigen and an effective amount of a second composition comprising an HIV antigen.

Abstract: The present invention relates to a composition for immunotherapy of allergic diseases, comprising house dust mite antigens and hyaluronic acid hydrogels as active ingredients. By using hyaluronic acid as a material, and forming a crosslinking with the house dust mite antigens via a photoinitiator and visible light, it can overcome the disadvantage of easy degradation and simultaneously exploit biocompatible features. Moreover, it can provide a large amount of antigens to immune cells with a single administration, and despite this, it does not induce foreign body reactions, drug reactions, or immune responses, while generating excellent immune tolerance effects. Its safety is outstanding and it does not require repeated injections over a long period. Thus, it is expected to be useful as a preventive or therapeutic agent for allergic diseases induced by house dust mites.

Abstract: The present invention relates to a method of treatment of breast cancer using combinations of an anti-interleukin-6 receptor antibody, a platinum-based antineoplastic drug, and a taxane.

Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.

Abstract: Methods for inducing plasticity in effector T cells or intermediate Treg cells to exhibit a regulatory T cell phenotype, treating an autoimmune disease, enriching Treg cells, and preparing a subject for an organ transplant are described. The methods involve the synergstic inhibition of eIF5A and Notch signaling. Also described are compositions and kits including an eIF5A inhibitor and a Notch signaling inhibitor.

Abstract: This disclosure provides a system for preventing or reducing side effects in a patent undergoing immunotherapy to remove diseased cells that express a target antigen: for example, by CAR T cell therapy. Side effects can ensue from concurrent depletion of hematopoietic cells bearing the same target antigen. A population of engineered hematopoietic cells is prepared by obtaining healthy hematopoietic cells from the patient or a third party donor, and using them to produce engineered hematopoietic cells. The engineered cells either do not express the target antigen, express it at a lower density, or express it in a modified form. The engineered hematopoietic cells are formulated for administration to the patient, whereupon they reconstitute hematopoietic cell function, thereby preventing or reducing the side effects.

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

Abstract: The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides improved cell compositions and methods for adoptive cell therapy, useful in the treatment of cancer. More specifically, embodiments of the invention employ the use of cell compositions comprising a high proportion of activated cytotoxic CD8+ cells and in particular CD8+NKG2D+granzyme-B+ cells characterized by enhanced cytotoxicity, to processes for their preparation from peripheral blood mononuclear cells (PBMC), and to their use in cancer management.

Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

Abstract: The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

Abstract: The present invention relates to the field of biomedicines. Specifically, the present invention relates to a chimeric antigen receptor (CAR) targeting EGFR, a CAR-T cell containing the CAR, as well as a preparation method and use thereof.

Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Embodiments of derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Abstract: Provided are conjugates, compositions, methods and uses related to treating a subject having a cancer, such as a cancer comprising a first tumor, a primary tumor, metastatic tumor cells, and/or invasive tumor cells. The methods include administering to the subject a targeting molecule that binds interleukin-2 receptor alpha chain (CD25) without substantially blocking or interfering with IL-2 signaling, conjugated with phthalocyanine dye, such as IR700, followed by illuminating a first tumor or primary tumor with a wavelength of light to activate the phthalocyanine dye. The methods and uses described herein provide for reduction, growth and elimination of tumors and tumor cells including first tumors, primary tumors, metastatic tumor cells, and/or invasive tumor cells. Also provided are methods and uses for enhancing systemic immunity against tumor growth in a subject having a cancer, a tumor or a lesion.

Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent

Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.

Abstract: Provided is an aqueous liquid preparation comprising arbekacin and/or a salt thereof and at least one water-soluble polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl cellulose, methyl cellulose, and polyvinylpyrrolidone.

Abstract: The invention relates to a conjugate comprising a saponin covalently linked to a ligand for ASGPR, the ligand comprising at least one GalNAc moiety, and comprising an oligonucleotide covalently linked to the saponin and the ligand for ASGPR. In addition, the invention relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention for use as a medicament.

Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Abstract: The present invention discloses novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I), (IIa)-(IIc), (III) and (IV), below.

Abstract: The present disclosure provides antibodies, and fragments thereof, conjugated to an oligonucleotide, wherein the oligonucleotide is not hybridized to a DNA dendrimer, compositions comprising the same, and uses thereof in methods of detection, methods of cell isolation, methods of depletion, methods of diagnosis, and methods of treatment.

Abstract: The present application pertains to pharmaceutical compositions for use in the treatment of cancer, whereby said pharmaceutical compositions are administered subcutaneously and wherein the pharmaceutical compositions of the invention comprise at least one conjugate that comprises an antibody which specifically binds to a cell surface antigen on a cancer cell and at least one amatoxin-linker payload. The present invention further pertains to methods of treating a patient afflicted with cancer using the pharmaceutical compositions of the invention.

Abstract: A method to upregulate CD46 cell surface expression and combination therapies for various cancers employing an anti-CD46 antibody, an androgen signaling inhibitor (ASI), a STAT3 inhibitor and/or a glucocorticoid receptor agonist or modular (SEGRAM) are provided.

Abstract: An antibody-drug conjugate, comprising a bispecific antibody targeting HER2 or an antigen-binding fragment thereof. Also provided are a preparation method for and an application of the antibody-drug conjugate, and a pharmaceutical composition comprising the antibody-drug conjugate. The antibody-drug conjugate can effectively kill tumors.

Abstract: The present disclosure provides ZnO-based compositions that stabilize mRNA and RNA as well as provide compositions and therapies to treat or prevent cancer and viral as well as microbial diseases.

Abstract: The present invention provides compositions comprising a recombinant AAV (rAAV) vector and one or more pharmaceutically acceptable excipients. The compositions have improved stability as compared to other rAAV compositions.

Abstract: The invention relates to transduction buffers and methods for transducing molecules into cells using said buffers. The invention also relates to pharmaceutical compositions comprising said transduction buffers and methods of treatment involving the use of said buffers or pharmaceutical compositions to treat diseases, in particular genetic diseases.

Abstract: The invention features pseudotyped viral particles (e.g., lentiviral or gammaretroviral particles) and compositions and methods of use thereof, where the viral particles comprise a VHH domain.

Abstract: The present invention provides, among other things, mRNA constructs and compositions and methods for reverse gene therapy, including administering to a subject in need of treatment a mRNA gene transfer construct comprising a reverse complement sequence encoding a protein of interest and a sequence encoding a human L1 retro-element.

Abstract: Provided herein are compositions and methods for suppressing mutant gene function using Cas13 nucleases that can be delivered to the spinal cord and brain to mediate the knockdown of genes that are causative for autosomal dominant neurodegenerative disorders.

Abstract: The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaf1V carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB 3, and COL7A1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvaf17-KRT5, or VTvaf17-KRT14, or VTvaf17-LAMB3, or VTvaf17-COL7A1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals. A method of obtaining the specified vector, the use of the vector, a strain of Escherichia coli carrying the specified vector, and a method of industrial production of the specified vector are also provided.

Abstract: Provided herein are expression constructs, viral genomes, and vectors for the expression of Kv8.2, as well as pharmaceutical compositions comprising the vectors disclosed herein. Also provided are methods of using the expression constructs and vectors disclosed herein, including methods of treating a retinal disease in a subject in need thereof, wherein the retinal disease is associated with one or more mutations in the KCNV2 gene, the method comprising administering to the subject a vector disclosed herein.

Abstract: Embodiments of the present invention generally relate to conjugates of heptamethine carbocyanine dye (HMCD)-chelator radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, in particular for internal radiotherapy and/or imaging of cancer. In particular, in embodiments, provided are DZ-1-Lys-DOTA conjugates complexed with Lutetium-177, Yttrium-90 or Gallium-68, or combinations thereof. Some embodiments provide improved radiotherapy with complexes of Lutetium-177 or Yttrium-90. Further embodiments provide improved radioimaging with Gallium-68 complexes, and their use. Yet further embodiments provide improved image-guided therapy by using matched theranostic pairs of such conjugates, wherein for therapy purposes the radiometal is selected from one or more of Lutetium-177, Yttrium-90, each of which for imaging purposes may be paired with Gallium-68, for improved image-guided radiotherapy.

Abstract: PARP inhibitor conjugates, including radiolabeled PARP inhibitor conjugates, and methods of treating cancer using the same.

Abstract: The present invention relates to the development of methods and tools effective for treating, preventing, and diagnosing cancer. Specifically, the present invention is directed to a radioisotope conjugated to an anti-oxMIF antibody (anti-oxMIF radioim-munoconjugate) with improved properties such as reduced aggregation potential and reduced hydrophobicity due to selected amino acid substitutions in the light and heavy chain variable domains and methods of treating, preventing, and diagnosing cancer comprising using the anti-oxMIF radioimmunoconjugate.

Abstract: Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.

Abstract: The present disclosure provides herein conjugates of anti-CLDN18.2 antibodies or antigen-binding fragments thereof with radionuclides, the pharmaceutical composition containing the same and the uses thereof in imaging, patient screening, treatment process monitoring and efficacy evaluation.

Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.

Abstract: A sterilization system of an embodiment includes a light source unit, a horizontal angle adjustment unit and/or a vertical angle adjustment unit, and a controller. The light source unit emits ultraviolet rays in a radiating form. The horizontal angle adjustment unit adjusts a horizontal angle of the light source unit by causing rotation of the light source unit in a horizontal direction. The vertical angle adjustment unit adjusts a vertical angle of the light source unit by causing rotation of the light source unit in a vertical direction. The controller captures a target of sterilization from a camera image, controls rotation of the horizontal angle adjustment unit and/or the vertical angle adjustment unit, and irradiates the target with the ultraviolet rays from the light source unit.

Abstract: It is provided a method for level regulation of feed water in a chamber of a steam sterilizer or in a steam generator with a chamber of a steam sterilizer connected therewith wherein the feed water is heated by means of a heating element and steam thereby is generated for the chamber. A temperature change rate of the heating element is determined and refeeding with feed water is effected in dependence on the determined temperature change rate of the heating element.

Abstract: A method of sterilizing biocontainers including irradiating a biocontainer and measuring a radiation dose received by the biocontainer. The method also includes determining an ageing time of the biocontainer after irradiation based on the radiation dose received by the biocontainer and preventing use of the biocontainer before the ageing time has elapsed.

Abstract: A cartridge loader is provided. The cartridge loader can include a loader body, a top loader bay slidingly engaged to the loader body, and a bottom loader bay slidingly engaged to the loader body. The cartridge loader can further include a cleaning assembly coupled to the loader body. The cartridge loader can be manipulated from a first configuration to a second configuration, such that when in the first configuration, the cartridge loader can receive a cartridge shield containing a cartridge therein, and when in the second configuration, if no cartridge shield is received, the cleaning assembly is configured to disinfect the cartridge loader.

Abstract: This disclosure includes a description of a sanitizing system for sanitizing a mobile electronic device comprising: a housing; a sanitizer contained within the housing configured to emit radiation with a sanitizing effect; and an entry system with a default closed position, the entry system being configured to permit a mobile electronic device to pass through the entry system and then automatically return to the default closed position, the entry system comprising a first outer enclosure and a second inner obstruction; wherein the entry system blocks radiation emitted within the sanitizing system to a level acceptable for consumer use, or wherein the second inner obstruction provides more radiation attenuation than the first outer enclosure, and/or wherein the combination of the first outer enclosure and the second inner obstruction provides more radiation attenuation than the first outer enclosure by itself. Disclosed are internal reflectors to help distribute sanitizing radiation generally evenly.

Abstract: Apparatus for treating an object which has a housing into which hot air and ultraviolet radiation are directed to impinge on the object which is located inside the housing, if the object is a container, inside the housing, the hot air and UV radiation are directed into an interior of the container.